Increasing Levels of Pretreatment HIV Drug Resistance and Safety Concerns for Dolutegravir Use In Women of Reproductive Age
September 1, 2019
Seth Inzaule; Michael Jordan; Amandine Cournil; Marco Vitoria; Giovanni Ravasi; Fatim Cham; Linh-Vi Le; Janet Dzangare; Ndapewa Hamunime; Nicholus Mutenda; Avelin Aghokeng; Annez Bissek; Serge Billong; Pontiano Kaleebu; Meg Doherty; Silvia Bertagnolio;
AIDS. 2019 Sep 1;33(11):1797-1799.
PMID: 31149946 | DOI: 10.1097/QAD.0000000000002277
Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIVdrug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safetyconcerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.